Pentixapharm Holding AG Plans IPO on Frankfurt Stock Exchange

Pentixapharm Holding AG, a subsidiary of Eckert & Ziegler SE, is planning an IPO on the Prime Standard of the Frankfurt Stock Exchange in Q4 2024. The company focuses on radiopharmaceuticals for diagnosis and therapy, including first-in-class treatments for blood cancers.

The IPO is intended to secure both short- and long-term financing. The lead candidate, PentixaFor, is in Phase III for primary aldosteronism, a significant cause of hypertension. Promising results from a small study in T-cell lymphomas have bolstered confidence in their candidate PentixaTher.

This move comes amid high market growth and intense M&A activity, highlighting the economic potential of radiopharmaceutical therapies. The IPO, led by BankM AG, aims to attract institutional and retail investors.

Through this strategic step, Pentixapharm seeks to strengthen its financial resources for pipeline development and secure long-term capital access.